Nkarta (NKTX) to Release Earnings on Thursday

Nkarta (NASDAQ:NKTX) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.

Nkarta Trading Down 2.4 %

Shares of NASDAQ:NKTX opened at $1.62 on Tuesday. The company has a 50 day moving average of $2.13 and a 200-day moving average of $3.07. The firm has a market cap of $114.32 million, a P/E ratio of -0.86 and a beta of 0.90. Nkarta has a twelve month low of $1.57 and a twelve month high of $13.90.

Analyst Upgrades and Downgrades

Separately, Mizuho reduced their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $15.00.

Insider Activity at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the sale, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.70% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.